Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045

This nationwide cohort demonstrated considerable differences in patient, disease and treatment characteristics as compared to patients in the KN-P arm, with generally less favorable prognostic characteristics and worse survival. Sensitivity analyses on patients with metachronous mUC or mUC of the upper urinary tract did not alter the findings. These findings highlight the importance of adequate patient selection according to the KEYNOTE-045 criteria while also accounting for disparities between patient populations in routine clinical practice and those in clinical trials.

Authors

Institutions

Publication Details

Journal
Cancer Treatment and Research Communications
Published
2025-01-01
DOI
https://doi.org/10.1016/j.ctarc.2025.100931
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045

Britt B.M. Suelmann, Katja K.H. Aben, Bart Rikhof, Mira D. Franken et al.
Cancer Treatment and Research Communications
Bladder and Urothelial Cancer Treatments
article

Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045

Britt B.M. Suelmann, Katja K.H. Aben, Bart Rikhof, Mira D. Franken, Niven Mehra, Anke Richters, Hans M. Westgeest, Debbie Robbrecht
article en

Abstract

This nationwide cohort demonstrated considerable differences in patient, disease and treatment characteristics as compared to patients in the KN-P arm, with generally less favorable prognostic characteristics and worse survival. Sensitivity analyses on patients with metachronous mUC or mUC of the upper urinary tract did not alter the findings. These findings highlight the importance of adequate patient selection according to the KEYNOTE-045 criteria while also accounting for disparities between patient populations in routine clinical practice and those in clinical trials.

Cancer Treatment and Research CommunicationsVol. 43
Radboud University Nijmegen (NL), Erasmus MC (NL), Medisch Centrum Leeuwarden (NL), Radboud University Medical Center (NL), University Medical Center Utrecht (NL), Amphia Ziekenhuis (NL), Canisius-Wilhelmina Ziekenhuis (NL), Zuyderland Medisch Centrum (NL), Netherlands Comprehensive Cancer Organisation (NL), Erasmus MC Cancer Institute (NL), Amsterdam University Medical Centers (NL), Rijnstate Hospital (NL), Meander Medisch Centrum (NL), Jeroen Bosch Ziekenhuis (NL)
Bristol-Myers Squibb, Astellas Pharma US, Merck KGaA, Amsterdam University Medical Centers, Universitair Medisch Centrum Utrecht, Maastricht Universitair Medisch Centrum, AstraZeneca Korea, Radboud Universitair Medisch Centrum
Good health and well-being
Openalex Percentile: Top 87%
Bladder and Urothelial Cancer Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.